Utility of C-reactive protein in assessing the disease severity and complications of community-acquired pneumonia

Clinical Microbiology and Infection

Volumn 15, Issue 11, 2009, Pages 1026-1032

  Hohenthal, U ^a   Hurme, S ^b   Helenius, H ^b   Heiro, M ^a   Meurman, O ^a   Nikoskelainen, J ^a   Kotilainen, P ^a  

^a TURKU UNIVERSITY HOSPITAL   (Finland)

^b UNIVERSITY OF TURKU   (Finland)

Author keywords

Aetiology; C reactive protein; Community acquired pneumonia; Complication; Disease severity

Indexed keywords

C REACTIVE PROTEIN;

ADULT; ARTICLE; BLOOD CULTURE; CHLAMYDOPHILA PNEUMONIAE; COMMUNITY ACQUIRED PNEUMONIA; DIAGNOSTIC VALUE; DISEASE CLASSIFICATION; DISEASE SEVERITY; FEMALE; HOSPITALIZATION; HUMAN; INFLUENZA VIRUS A; INFLUENZA VIRUS B; LEGIONELLA PNEUMOPHILA; MAJOR CLINICAL STUDY; MALE; PNEUMONIA SEVERITY INDEX; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SPUTUM CULTURE; STREPTOCOCCUS PNEUMONIAE;

EID: 70449105200     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/j.1469-0691.2009.02856.x     Document Type: Article

References (35)

1. Yentis SM, Soni N, Sheldon J. C-reactive protein as an indicator of resolution of sepsis in the intensive care unit. Intensive Care Med 1995, 21:602-605.
2. Póvoa P, Coelho L, Almeida E. C-reactive protein as a marker of infection in critically ill patients. Clin Microbiol Infect 2005, 11:101-108.
3. Póvoa P. C-reactive protein: a valuable marker of sepsis. Intensive Care Med 2002, 28:235-243.
4. Gaïni S, Koldkjær OG, Pedersen C, Pedersen SS. Procalcitonin, lipopolysaccharide-binding protein, interleukin-6 and C-reactive protein in community-acquired infections and sepsis: a prospective study. Crit Care 2006, 10:R53.
5. Hansson LO, Axelsson G, Linné T, Aurelius E, Lindquist L. Serum C-reactive protein in the differential diagnosis of acute meningitis. Scand J Infect Dis 1993, 25:625-630.
6. Sormunen P, Kallio MJ, Kilpi T, Peltola H. C-reactive protein is useful in distinguishing Gram stain-negative bacterial meningitis from viral meningitis in children. J Pediatr 1999, 134:725-729.
7. Hogevik H, Olaison L, Andersson R, Alestig K. C-reactive protein is more sensitive than erythrocyte sedimentation rate for diagnosis of infective endocarditis. Infection 1997, 25:82-85.
8. Heiro M, Helenius H, Sundell J. Utility of serum C-reactive protein in assessing the outcome of infective endocarditis. Eur Heart J 2005, 26:1873-1881.
9. Smith RP, Lipworth BJ. C-reactive protein in simple community-acquired pneumonia. Chest 1995, 107:1028-1031.
10. Castro-Guardiola A, Armengou-Arxé A, Viejo-Rodríguez AL, Peñarroja-Matutano G, Garcia-Bragado F. Differential diagnosis between community-acquired pneumonia and non-pneumonia diseases of the chest in the emergency ward. Eur J Intern Med 2000, 11:334-339.
11. Almirall J, Bolíbar I, Toran P. Contribution of C-reactive protein to the diagnosis and assessment of severity of community-acquired pneumonia. Chest 2004, 125:1335-1342.
12. Flanders SA, Stein J, Shochat G. Performance of a bedside C-reactive protein test in the diagnosis of community-acquired pneumonia in adults with acute cough. Am J Med 2004, 116:529-535.
13. Holm A, Pedersen SS, Nexoe J. Procalcitonin versus C-reactive protein for predicting pneumonia in adults with lower respiratory tract infection in primary care. Br J Gen Pract 2007, 57:555-560.
14. Örtqvist T, Hedlund J, Wretlind B, Carlström A, Kalin M. Diagnostic and prognostic value of interleukin-6 and C-reactive protein in community-acquired pneumonia. Scand J Infect Dis 1995, 27:457-462.
15. Kragsbjerg P, Jones I, Vikerfors T, Holmberg H. Diagnostic value of blood cytokine concentrations in acute pneumonia. Thorax 1995, 50:1253-1257.
16. Kosmas EN, Baxevanis CN, Papamichail M, Kordossis T. Daily variation in circulating cytokines and acute-phase proteins correlates with clinical and laboratory indices in community-acquired pneumonia. Eur J Clin Invest 1997, 27:308-315.
17. Hedlund J, Hansson LO. Procalcitonin and C-reactive protein levels in community-acquired pneumonia: correlation with etiology and prognosis. Infection 2000, 28:68-73.
18. Garcia Vázquez E, Martínez JA, Mensa J. C-reactive protein levels in community-acquired pneumonia. Eur Respir J 2003, 21:702-705.
19. Hedlund J, Hansson LO, Örtqvist T. Short- and long-term prognosis for middle-aged and elderly patients hospitalized with community-acquired pneumonia: impact of nutritional and inflammatory factors. Scand J Infect Dis 1995, 27:32-37.
20. Smith RP, Lipworth BJ, Cree IA, Spiers EM, Winter JH. C-reactive protein. A clinical marker in community-acquired pneumonia. Chest 1995, 108:1288-1291.
21. Igonin AA, Armstrong VW, Shipkova M, Lazareva NB, Kukes VG, Oellerich M. Circulating cytokines as markers of systemic inflammatory response in severe community-acquired pneumonia. Clin Biochem 2004, 37:204-209.
22. Chalmers JD, Singanayagam A, Hill AT. C-reactive protein is an independent predictor of severity in community-acquired pneumonia. Am J Med 2008, 121:219-225.
23. Brunkhorst FM, Al-Nawas B, Krummenauer F, Forycki ZF, Shah PM. Procalcitonin, C-reactive protein and APACHE II score for risk evaluation in patients with severe pneumonia. Clin Microbiol Infect 2002, 8:93-100.
24. Hohenthal U, Vainionpää R, Meurman O. Aetiological diagnosis of community acquired pneumonia: utility of rapid microbiological methods with respect to disease severity. Scand J Infect Dis 2008, 40:131-138.
25. Fine MJ, Auble TE, Yealy DM. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 1997, 336:243-250.
26. Halm EA, Fine MJ, Marrie TJ. Time to clinical stability in patients hospitalized with community-acquired pneumonia: implications for practice guidelines. JAMA 1998, 279:1452-1457.
27. Renaud B, Coma E, Hayon J. Investigation of the ability of the Pneumonia Severity Index to accurately predict clinically relevant outcomes: a European study. Clin Microbiol Infect 2007, 13:923-931.
28. Man SY, Lee N, Ip M. Prospective comparison of three predictive rules for assessing severity of community-acquired pneumonia in Hong Kong. Thorax 2007, 62:348-353.
29. Garau J, Baquero F, Pérez-Trallero E. Factors impacting on length of stay and mortality of community-acquired pneumonia. Clin Microbiol Infect 2008, 14:322-329.
30. Fine MJ, Smith MA, Carson CA. Prognosis and outcomes of patients with community-acquired pneumonia. A meta-analysis. JAMA 1996, 275:134-141.
31. Musher DM, Alexandraki I, Graviss EA. Bacteremic and nonbacteremic pneumococcal pneumonia. A prospective study. Medicine (Baltimore) 2000, 79:210-221.
32. Mandell LA, Wunderink RG, Anzueto A. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007, 44(suppl 2):27-72.
33. Gaïni S, Koldkjær OG, Møller HJ, Pedersen C, Pedersen SS. A comparison of high-mobility group-box 1 protein, lipopolysaccharide-binding protein and procalcitonin in severe community-acquired infections and bacteraemia: a prospective study. Crit Care 2007, 11:R76.
34. Menéndez R, Cavalcanti M, Reyes S. Markers of treatment failure in hospitalised community acquired pneumonia. Thorax 2008, 63:447-452.
35. Bruns AH, Oosterheert JJ, Hak E, Hoepelman AI. Usefulness of consecutive C-reactive protein measurements in follow-up of severe community-acquired pneumonia. Eur Respir J 2008, 32:726-732.